What is Amylyx Pharmaceuticals, Inc.'s earnings per share (EPS)?

Amylyx Pharmaceuticals, Inc. (AMLX) reported diluted earnings per share of -$1.53 for fiscal year 2025. This represents a 65.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Amylyx Pharmaceuticals, Inc. (AMLX) Financials

AMLX

FY2025 annual

Revenue $0 -100.0% YoY

Net Income -$144.7M +52.0% YoY

EPS (Diluted) -$1.53 +65.5% YoY

Free Cash Flow -$123.5M +26.4% YoY

Market Cap $3.5B as of Oct 3, 2026

Price / Sales n/m revenue is not positive, FY2025

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 14.8x on $239.2M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AMLX SEC filings page.

Amylyx Pharmaceuticals, Inc. (AMLX) reported $0 in revenue for fiscal year 2025, down 100.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI AMLX FY2025 2026-10-04

The business remains loss-making, but 2025’s smaller deficit came from lower spending and financing capacity, not demonstrated operating scale.

Net loss narrowed from $302M in FY2024 to $145M in FY2025, but that improvement coincided with combined SG&A and R&D spending falling from $218M to $153M. The pattern points to cost reduction as the main mechanism, rather than scale-driven operating leverage.

Total liabilities were $27.4M against $332.6M of assets, a balance sheet funded far more by equity than obligations. Liquidity equaled 30.8 months of the latest reported annual operating outflow, while the current ratio was 14.3x, indicating substantial short-term financial flexibility.

FY2025 operating cash flow of -$123M tracked the $145M net loss, so the accounting loss broadly translated into cash use rather than arising mainly from noncash charges. The financing inflow of $257M alongside a higher share count is consistent with external capital supporting the balance sheet while operations remained cash-consuming.

Financial Health Signals

Financial health score not available

Amylyx Pharmaceuticals, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Safe

74.11

Amylyx Pharmaceuticals, Inc. scores 74.11, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($3.5B) relative to total liabilities ($27.4M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/7

Amylyx Pharmaceuticals, Inc. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Amylyx Pharmaceuticals, Inc. reported a net loss of $144.7M while operations used $123.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$45.6M

YoY-6.9%

QoQ-4.5%

Amylyx Pharmaceuticals, Inc.'s EBITDA was -$45.6M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 6.9% from the same quarter a year earlier. Against the prior quarter it is down 4.5%.

Net Income

-$43.4M

YoY-4.8%

QoQ-5.2%

Amylyx Pharmaceuticals, Inc. reported -$43.4M in net income in Q2 2026. This represents a decrease of 4.8% from the same quarter a year earlier. Against the prior quarter it is down 5.2%.

EPS (Diluted)

-$0.39

YoY+15.2%

QoQ-5.4%

Amylyx Pharmaceuticals, Inc. earned -$0.39 per diluted share (EPS) in Q2 2026. This represents an increase of 15.2% from the same quarter a year earlier. Against the prior quarter it is down 5.4%.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$49.3M

YoY-15.1%

QoQ-78.5%

Amylyx Pharmaceuticals, Inc. held $49.3M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

111M

YoY+25.0%

QoQ+0.2%

Amylyx Pharmaceuticals, Inc. had 111M shares outstanding in Q2 2026. This represents an increase of 25.0% from the same quarter a year earlier. Against the prior quarter it is up 0.2%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-18.2%

YoY+6.5pp

QoQ-3.0pp

Amylyx Pharmaceuticals, Inc.'s ROE was -18.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 6.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.0 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$23.8M

YoY-12.7%

QoQ-13.9%

Amylyx Pharmaceuticals, Inc. invested $23.8M in research and development in Q2 2026. This represents a decrease of 12.7% from the same quarter a year earlier. Against the prior quarter it is down 13.9%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

AMLX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AMLX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K
Revenue	N/A	$0-100.0%	$87.4M-77.1%	$380.8M+1612.9%	$22.2M+7700.0%	$285K
Cost of Revenue	N/A	$0-100.0%	$6.0M-76.6%	$25.4M+750.0%	$3.0M	N/A
Gross Profit	N/A	$0-100.0%	$81.4M-77.1%	$355.3M+1747.2%	$19.2M	N/A
R&D Expenses	N/A	$90.4M-13.1%	$104.1M-18.8%	$128.2M+37.2%	$93.5M+112.2%	$44.0M
SG&A Expenses	N/A	$62.9M-45.0%	$114.3M-39.3%	$188.4M+48.2%	$127.1M+226.5%	$38.9M
Operating Income	N/A	-$153.3M+51.3%	-$314.7M-911.1%	$38.8M+119.3%	-$201.3M-143.5%	-$82.7M
EBITDA	N/A	-$152.8M+51.3%	-$313.8M-886.7%	$39.9M+119.9%	-$200.9M-143.1%	-$82.6M
Income Tax	N/A	$46K+111.7%	-$393K-107.8%	$5.0M+549.4%	$774K	N/A
Net Income	N/A	-$144.7M+52.0%	-$301.7M-712.4%	$49.3M+124.8%	-$198.4M-125.6%	-$87.9M
EPS (Basic)	N/A	-$1.53+65.5%	-$4.43-706.8%	$0.73+121.5%	-$3.39+74.6%	-$13.35
EPS (Diluted)	-$1.41	-$1.53+65.5%	-$4.43-732.9%	$0.70+120.6%	-$3.39	-$13.35
Diluted Shares (Avg)	N/A	95M+38.8%	68M-2.6%	70M+19.7%	58M	7M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	N/A	N/A	N/A	$0-100.0%	$0	$0-100.0%	N/A	$416K-99.6%
Cost of Revenue	N/A	N/A	N/A	$0	$0-100.0%	$0-100.0%	N/A	$0-100.0%
Gross Profit	N/A	N/A	N/A	$0-100.0%	$0+100.0%	$0-100.0%	N/A	$416K-99.6%
R&D Expenses	$23.8M-12.7%	$27.6M+24.8%	N/A	$19.9M-6.5%	$27.2M+16.6%	$22.1M-39.6%	N/A	$21.2M-29.3%
SG&A Expenses	$21.9M+40.2%	$16.2M+3.1%	N/A	$16.2M-9.3%	$15.6M-27.7%	$15.7M-72.8%	N/A	$17.8M-63.4%
Operating Income	-$45.7M-6.6%	-$43.8M-15.8%	N/A	-$36.0M+52.4%	-$42.9M+43.8%	-$37.8M+69.0%	N/A	-$75.7M-504.2%
EBITDA	-$45.6M-6.9%	-$43.7M-16.0%	N/A	-$35.9M+52.4%	-$42.7M+43.9%	-$37.6M+69.1%	N/A	-$75.4M-496.6%
Income Tax	N/A	N/A	N/A	$0	$0	$0-100.0%	N/A	$0-100.0%
Net Income	-$43.4M-4.8%	-$41.3M-15.0%	N/A	-$34.4M+52.7%	-$41.4M+43.0%	-$35.9M+69.8%	N/A	-$72.7M-448.0%
EPS (Basic)	-$0.39+15.2%	-$0.37+11.9%	-$0.28+48.1%	-$0.37+65.4%	-$0.46+57.0%	-$0.42+76.0%	-$0.54-871.4%	-$1.07-445.2%
EPS (Diluted)	-$0.39+15.2%	-$0.37+11.9%	-$0.28+48.1%	-$0.37+65.4%	-$0.46+57.0%	-$0.42+76.0%	-$0.54-871.4%	-$1.07-456.7%
Diluted Shares (Avg)	111M+24.7%	111M+29.0%	N/A	93M+37.1%	89M+31.0%	86M+26.3%	N/A	68M-2.4%

Not reported in any period shown, so not listed: Interest Expense.

AMLX Balance Sheet

AMLX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K
Total Assets	$332.6M+71.8%	$193.6M-62.6%	$517.5M+32.2%	$391.5M+270.6%	$105.6M
Current Assets	$323.7M+70.9%	$189.4M-59.2%	$464.7M+21.6%	$382.1M+264.1%	$105.0M
Cash & Equivalents	$226.7M+192.9%	$77.4M-54.5%	$170.2M+172.2%	$62.5M+24.6%	$50.2M
Short-Term Investments	$90.3M-8.9%	$99.1M-50.7%	$201.2M-29.3%	$284.4M+519.3%	$45.9M
Inventory	N/A	$0-100.0%	$38.3M+292.3%	$9.8M	N/A
Accounts Receivable	$88K-80.3%	$447K-98.9%	$40.0M+161.7%	$15.3M	N/A
Long-Term Investments	$0	$0	$0	$0	$0
Total Liabilities	$27.4M-5.1%	$28.9M-65.6%	$84.0M+65.2%	$50.8M-80.2%	$256.8M
Current Liabilities	$22.7M-20.1%	$28.4M-65.4%	$82.0M+76.0%	$46.6M+167.9%	$17.4M
Non-Current Liabilities	$4.7M+914.7%	$463K-76.6%	$2.0M-53.3%	$4.2M-98.2%	$239.4M
Total Equity	$305.3M+85.3%	$164.8M-62.0%	$433.4M+27.3%	$340.6M+325.3%	-$151.2M
Retained Earnings	-$751.4M-23.9%	-$606.7M-98.9%	-$304.9M+13.9%	-$354.2M-127.3%	-$155.8M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$264.6M+36.0%	$293.6M+33.7%	$332.6M+71.8%	$362.7M+44.7%	$194.6M-41.4%	$219.7M-47.4%	$193.6M-62.6%	$250.7M-46.3%
Current Assets	$256.3M+37.2%	$285.0M+31.9%	$323.7M+70.9%	$353.4M+44.1%	$186.9M-42.8%	$216.1M-47.4%	$189.4M-59.2%	$245.3M-43.5%
Cash & Equivalents	$49.3M-15.1%	$229.1M+283.4%	$226.7M+192.9%	$225.2M+213.4%	$58.1M-22.6%	$59.8M-65.0%	$77.4M-54.5%	$71.8M-46.9%
Short-Term Investments	$201.4M+64.1%	$50.6M-64.9%	$90.3M-8.9%	$118.8M-26.9%	$122.7M-47.7%	$144.3M-28.8%	$99.1M-50.7%	$162.6M-26.0%
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	N/A
Accounts Receivable	N/A	N/A	$88K-80.3%	$132K-92.4%	$103K-97.5%	$300K-98.5%	$447K-98.9%	$1.7M-94.1%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$25.4M-5.0%	$20.4M+12.0%	$27.4M-5.1%	$30.7M-43.6%	$26.7M-62.3%	$18.3M-80.4%	$28.9M-65.6%	$54.5M+13.1%
Current Liabilities	$21.1M-1.3%	$16.0M-11.0%	$22.7M-20.1%	$25.8M-52.2%	$21.4M-69.4%	$17.9M-80.4%	$28.4M-65.4%	$53.9M+18.2%
Non-Current Liabilities	$4.2M-19.8%	$4.5M+1268.8%	$4.7M+914.7%	$5.0M+732.6%	$5.3M+586.1%	$327K-76.3%	$463K-76.6%	$595K-76.8%
Total Equity	$239.2M+42.5%	$273.2M+35.6%	$305.3M+85.3%	$332.0M+69.2%	$167.9M-35.8%	$201.4M-37.9%	$164.8M-62.0%	$196.2M-53.1%
Retained Earnings	-$836.1M-22.2%	-$792.7M-23.4%	-$751.4M-23.9%	-$718.4M-26.2%	-$684.0M-37.8%	-$642.6M-51.6%	-$606.7M-98.9%	-$569.1M-83.8%

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

AMLX Cash Flow Statement

AMLX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K
Operating Cash Flow	-$126.6M	-$123.3M+26.4%	-$167.6M-1506.6%	$11.9M+106.6%	-$179.9M-140.5%	-$74.8M
Depreciation & Amortization	N/A	$525K-41.9%	$904K-16.9%	$1.1M+123.4%	$487K+836.5%	$52K
Stock-Based Compensation	N/A	$27.6M-16.3%	$33.0M-11.1%	$37.2M+71.1%	$21.7M+592.4%	$3.1M
Capital Expenditures	N/A	$138K-12.1%	$157K-87.3%	$1.2M-50.9%	$2.5M+615.6%	$353K
Free Cash Flow	N/A	-$123.5M+26.4%	-$167.8M-1671.5%	$10.7M+105.9%	-$182.4M-142.7%	-$75.2M
Investing Cash Flow	-$78.8M	$14.0M-81.4%	$75.7M-17.8%	$92.1M+138.5%	-$239.0M-415.0%	-$46.4M
Financing Cash Flow	$196.1M	$257.0M+73758.9%	$348K-90.2%	$3.5M-99.2%	$431.8M+172.4%	$158.5M
Dividends Paid	$0	$0	$0	$0	$0	$0

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$31.4M-24.5%	-$36.9M+7.4%	-$27.9M	-$30.4M+26.9%	-$25.2M+62.1%	-$39.8M-8044.0%	N/A	-$41.6M-704.2%
Depreciation & Amortization	$43K-69.5%	$98K-37.2%	$108K	$120K-45.7%	$141K-32.2%	$156K-50.5%	N/A	$221K-26.8%
Stock-Based Compensation	$8.3M+13.2%	$6.1M-10.4%	N/A	$7.1M+4.0%	$7.3M-23.2%	$6.8M-31.1%	N/A	$6.8M-33.1%
Capital Expenditures	N/A	N/A	$86K	$24K+26.3%	$17K-80.9%	$11K-83.6%	N/A	-$19K-94.7%
Free Cash Flow	N/A	N/A	-$28.0M	-$30.4M+26.9%	-$25.3M+62.1%	-$39.8M-7064.6%	N/A	-$41.6M-652.6%
Investing Cash Flow	-$149.8M-751.5%	$36.3M+183.1%	$29.5M	$5.2M-86.5%	$23.0M+179.4%	-$43.7M-5430.8%	N/A	$38.8M+135.9%
Financing Cash Flow	$1.5M+4871.0%	$3.2M-95.1%	-$208K	$191.6M+239407.5%	-$31K-214.8%	$65.7M+50023.7%	N/A	$80K-91.0%
Dividends Paid	$0	$0	$0	$0	$0	$0	N/A	$0

Not reported in any period shown, so not listed: Share Buybacks.

AMLX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AMLX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K
Gross Margin	N/A	93.2%-0.1pp	93.3%+6.8pp	86.5%	N/A
Operating Margin	N/A	-360.2%	10.2%	-905.7%	-29013.3%
Net Margin	N/A	-345.4%	12.9%	-892.4%	-30853.0%
Return on Equity	-47.4%+135.7pp	-183.1%-194.5pp	11.4%+69.6pp	-58.2%	N/A
Return on Assets	-43.5%+112.3pp	-155.8%-165.3pp	9.5%+60.2pp	-50.7%+32.6pp	-83.3%
Current Ratio	14.27+7.6x	6.67+1.0x	5.66-2.5x	8.20+2.2x	6.03
Debt-to-Equity	0.09-0.1x	0.180.0x	0.190.0x	0.15	N/A
Asset Turnover	0.00-0.5x	0.45-0.3x	0.74+0.7x	0.06+0.1x	0.00
FCF Margin	N/A	-192.1%	2.8%	-820.5%	-26369.1%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	100.0%+5.1pp
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-18187.7%
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-17476.9%
Return on Equity	-18.2%+6.5pp	-15.1%+2.7pp	N/A	-10.4%+26.7pp	-24.7%+3.1pp	-17.8%+18.8pp	N/A	-37.1%-42.0pp
Return on Assets	-16.4%+4.9pp	-14.1%+2.3pp	N/A	-9.5%+19.5pp	-21.3%+0.6pp	-16.4%+12.1pp	N/A	-29.0%-33.5pp
Current Ratio	12.12+3.4x	17.85+5.8x	14.27+7.6x	13.70+9.2x	8.72+4.1x	12.05+7.6x	6.67+1.0x	4.55-5.0x
Debt-to-Equity	0.11-0.1x	0.070.0x	0.09-0.1x	0.09-0.2x	0.16-0.1x	0.09-0.2x	0.180.0x	0.28+0.2x
Asset Turnover	N/A	N/A	N/A	0.000.0x	0.000.0x	0.00-0.2x	N/A	0.00-0.2x
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-9997.4%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Amylyx Pharmaceuticals, Inc. AMLX	FY2025	$0	-$144.7M	N/A	$3.5B	—
Stoke Therapeutics, Inc. STOK	FY2025	$184.4M	-$6.9M	-3.7%	$1.7B	83/100
Tourmaline Bio, Inc. TRML	FY2024	N/A	-$73.2M	N/A	$1.2B	—
Dianthus Therapeutics, Inc. DNTH	FY2025	$2.0M	-$162.3M	N/A	$4.9B	55/100
LENZ Therapeutics, Inc. LENZ	FY2025	$19.1M	-$82.1M	N/A	$112.5M	56/100
Xeris Biopharma Holdings, Inc. XERS	FY2025	$291.8M	$554K	0.2%	$1.7B	37/100

Where Amylyx Pharmaceuticals, Inc. Ranks

Frequently Asked Questions

What is Amylyx Pharmaceuticals, Inc.'s annual revenue?

Amylyx Pharmaceuticals, Inc. (AMLX) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Amylyx Pharmaceuticals, Inc.'s revenue growing?

Amylyx Pharmaceuticals, Inc. (AMLX) revenue declined by 100.0% year-over-year, from $87.4M to $0 in fiscal year 2025.

Is Amylyx Pharmaceuticals, Inc. profitable?

No, Amylyx Pharmaceuticals, Inc. (AMLX) reported a net income of -$144.7M in fiscal year 2025.

What is Amylyx Pharmaceuticals, Inc.'s EBITDA?

Amylyx Pharmaceuticals, Inc. (AMLX) had EBITDA of -$152.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Amylyx Pharmaceuticals, Inc.'s return on equity (ROE)?

Amylyx Pharmaceuticals, Inc. (AMLX) has a return on equity of -47.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Amylyx Pharmaceuticals, Inc.'s free cash flow?

Amylyx Pharmaceuticals, Inc. (AMLX) recorded an outflow of $123.5M in free cash flow during fiscal year 2025. This represents a 26.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Amylyx Pharmaceuticals, Inc.'s operating cash flow?

Amylyx Pharmaceuticals, Inc. (AMLX) recorded an outflow of $123.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Amylyx Pharmaceuticals, Inc.'s total assets?

Amylyx Pharmaceuticals, Inc. (AMLX) had $332.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Amylyx Pharmaceuticals, Inc.'s capital expenditures?

Amylyx Pharmaceuticals, Inc. (AMLX) invested $138K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Amylyx Pharmaceuticals, Inc. spend on research and development?

Amylyx Pharmaceuticals, Inc. (AMLX) invested $90.4M in research and development during fiscal year 2025.

How many shares does Amylyx Pharmaceuticals, Inc. have outstanding?

Amylyx Pharmaceuticals, Inc. (AMLX) had 111M shares outstanding as of fiscal year 2025.

What is Amylyx Pharmaceuticals, Inc.'s current ratio?

Amylyx Pharmaceuticals, Inc. (AMLX) had a current ratio of 14.27 as of fiscal year 2025, which is generally considered healthy.

What is Amylyx Pharmaceuticals, Inc.'s debt-to-equity ratio?

Amylyx Pharmaceuticals, Inc. (AMLX) had a debt-to-equity ratio of 0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Amylyx Pharmaceuticals, Inc.'s return on assets (ROA)?

Amylyx Pharmaceuticals, Inc. (AMLX) had a return on assets of -43.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Amylyx Pharmaceuticals, Inc.'s P/E ratio?

Amylyx Pharmaceuticals, Inc. (AMLX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $3.5B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Amylyx Pharmaceuticals, Inc.'s price-to-sales ratio?

Amylyx Pharmaceuticals, Inc. (AMLX) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $3.5B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Amylyx Pharmaceuticals, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Amylyx Pharmaceuticals, Inc. (AMLX) held $317.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $123.3M over that year. Dividing the one by the other, the reported balance equals about 31 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Amylyx Pharmaceuticals, Inc.'s Altman Z-Score?

Amylyx Pharmaceuticals, Inc. (AMLX) has an Altman Z-Score of 74.11, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Amylyx Pharmaceuticals, Inc.'s Piotroski F-Score?

Amylyx Pharmaceuticals, Inc. (AMLX) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Amylyx Pharmaceuticals, Inc.'s earnings high quality?

Amylyx Pharmaceuticals, Inc. (AMLX) reported a net loss of $144.7M while operations used $123.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.